Zobrazeno 1 - 10
of 3 427
pro vyhledávání: '"Interleukin-6 receptor"'
Autor:
Mittenbühler MJ; Max Planck Institute for Metabolism Research, Center for Endocrinology, Diabetes and Preventive Medicine (CEDP), Cologne, 50931, Germany., Sprenger HG; Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (CECAD), Germany; Max Planck Institute for Biology of Ageing, Cologne, 50931, Germany., Gruber S; Max Planck Institute for Metabolism Research, Center for Endocrinology, Diabetes and Preventive Medicine (CEDP), Cologne, 50931, Germany., Wunderlich CM; Max Planck Institute for Metabolism Research, Center for Endocrinology, Diabetes and Preventive Medicine (CEDP), Cologne, 50931, Germany., Kern L; Max Planck Institute for Metabolism Research, Center for Endocrinology, Diabetes and Preventive Medicine (CEDP), Cologne, 50931, Germany., Brüning JC; Max Planck Institute for Metabolism Research, Center for Endocrinology, Diabetes and Preventive Medicine (CEDP), Cologne, 50931, Germany; Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (CECAD), Germany., Wunderlich FT; Max Planck Institute for Metabolism Research, Center for Endocrinology, Diabetes and Preventive Medicine (CEDP), Cologne, 50931, Germany; Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (CECAD), Germany. Electronic address: Thomas.wunderlich@sf.mpg.de.
Publikováno v:
Molecular metabolism [Mol Metab] 2018 Nov; Vol. 17, pp. 122-133. Date of Electronic Publication: 2018 Sep 05.
Autor:
Hagenstein J; III. Department of Medicine and., Melderis S; III. Department of Medicine and., Nosko A; III. Department of Medicine and., Warkotsch MT; III. Department of Medicine and., Richter JV; III. Department of Medicine and., Ramcke T; III. Department of Medicine and., Herrnstadt GR; III. Department of Medicine and., Scheller J; Medical Faculty, Institute of Biochemistry and Molecular Biology II, Heinrich-Heine University, Dusseldorf, Germany., Yan I; Institute for Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; and., Mittrücker HW; Institute for Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; and., Kluger MA; III. Department of Medicine and., Steinmetz OM; III. Department of Medicine and o.steinmetz@uke.de.
Publikováno v:
Journal of the American Society of Nephrology : JASN [J Am Soc Nephrol] 2019 Aug; Vol. 30 (8), pp. 1439-1453. Date of Electronic Publication: 2019 Jul 16.
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Interleukin-6 (IL-6) plays a crucial role in the pathogenesis of cardiovascular disease (CVD), and IL-6 receptor (IL-6R) blockade has emerged as a promising therapeutic option. However, their specific therapeutic effects in different types o
Externí odkaz:
https://doaj.org/article/b5cb279341bb4d8a8643f8e6a61cbbb9
Autor:
Schillinger O; Institute of Complex Systems, Structural Biochemistry (ICS-6), Forschungszentrum Jülich , 52425 Jülich, Germany.; Institut für Physikalische Biologie, Heinrich-Heine-Universität , 40225 Düsseldorf, Germany., Panwalkar V; Institute of Complex Systems, Structural Biochemistry (ICS-6), Forschungszentrum Jülich , 52425 Jülich, Germany.; Institut für Physikalische Biologie, Heinrich-Heine-Universität , 40225 Düsseldorf, Germany., Strodel B; Institute of Complex Systems, Structural Biochemistry (ICS-6), Forschungszentrum Jülich , 52425 Jülich, Germany.; Institut für Theoretische Chemie und Computerchemie, Heinrich-Heine-Universität , 40225 Düsseldorf, Germany., Dingley AJ; Institute of Complex Systems, Structural Biochemistry (ICS-6), Forschungszentrum Jülich , 52425 Jülich, Germany.; Institut für Physikalische Biologie, Heinrich-Heine-Universität , 40225 Düsseldorf, Germany.
Publikováno v:
The journal of physical chemistry. B [J Phys Chem B] 2017 Aug 31; Vol. 121 (34), pp. 8113-8122. Date of Electronic Publication: 2017 Aug 23.
Autor:
Nitz R; Institute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich-Heine-University, 40225, Düsseldorf, Germany., Lokau J; Institute of Biochemistry, Kiel University, 24118, Kiel, Germany., Aparicio-Siegmund S; Institute of Biochemistry, Kiel University, 24118, Kiel, Germany., Scheller J; Institute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich-Heine-University, 40225, Düsseldorf, Germany., Garbers C; Institute of Biochemistry, Kiel University, 24118, Kiel, Germany. Electronic address: cgarbers@biochem.uni-kiel.de.
Publikováno v:
Biochimie [Biochimie] 2015 Dec; Vol. 119, pp. 175-82. Date of Electronic Publication: 2015 Nov 10.
Autor:
Kelesidis T; Department of Medicine, Division of Infectious Disease, David Geffen School of Medicine at UCLA, Los Angeles, California, USA., Zhang Y; Department of Medicine, Division of Infectious Disease, David Geffen School of Medicine at UCLA, Los Angeles, California, USA., Tran E; Department of Medicine, Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA., Sosa G; Department of Medicine, Division of Infectious Disease, David Geffen School of Medicine at UCLA, Los Angeles, California, USA., Middlekauff HR; Department of Medicine, Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. Electronic address: hmiddlekauff@mednet.ucla.edu.
Publikováno v:
The Canadian journal of cardiology [Can J Cardiol] 2021 Aug; Vol. 37 (8), pp. 1175-1180. Date of Electronic Publication: 2021 May 21.
Autor:
A. M. Lila, I. Z. Gaydukova, O. N. Anoshenkova, I. G. Bannikova, I. B. Vinogradova, M. L. Goldman, S. Yu. Davidian, L. P. Evstigneeva, O. E. Epifanova, E. V. Zemerova, A. I. Zagrebneva, L. V. Ivanova, A. K. Karibova, I. V. Menshikova, O. N. Mironenko, M. P. Mikhailova, N. E. Nikulenkova, I. M. Patrikeeva, T. V. Plaksina, G. R. Savvina, R. R. Samigullina, L. E. Sarantseva, J. V. Usacheva, O. P. Ukhanova, G. F. Fatkhullina, A. L. Chudinov, I. A. Shafieva, S. P. Yakupova
Publikováno v:
Современная ревматология, Vol 18, Iss 3, Pp 32-43 (2024)
The efficacy and safety of levilimab (LVL) in patients with active rheumatoid arthritis (RA) has been confirmed in controlled clinical trials. This article presents the results of a preliminary analysis of a non-interventional observational study of
Externí odkaz:
https://doaj.org/article/4031788a32de403ebea6e82d4f01065d
Autor:
Lee JS; Roche, Nutley, NJ, USA., Chapman MJ; INSERM Dyslipidemia and Atherosclerosis Research Unit, Pitié-Salpêtrière University Hospital, Paris, France., Piraino P; Pvalue Research S.R.L, Piacenza, Italy., Lamerz J; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland., Schindler T; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland., Cutler P; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland., Dernick G; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland.
Publikováno v:
Proteomics. Clinical applications [Proteomics Clin Appl] 2016 Feb; Vol. 10 (2), pp. 183-94. Date of Electronic Publication: 2015 Sep 28.
Publikováno v:
Poultry Science, Vol 103, Iss 9, Pp 104044- (2024)
ABSTRACT: Protected biofactors and antioxidants (PBA), and protected biofactors and antioxidants with protected organic acids and essential oils (PBA+POAEO) have been shown to have benefits in stressed or challenged birds. Here, we describe the immun
Externí odkaz:
https://doaj.org/article/61374356fea04c99a0b7f8fa663560aa
Autor:
Patrick-Pascal Strunz, Linus Maximilian Risser, Matthias Englbrecht, Torsten Witte, Matthias Froehlich, Marc Schmalzing, Michael Gernert, Sebastian Hueper, Peter Bartz-Bazzanella, Cay von der Decken, Kirsten Karberg, Georg Gauler, Susanna Späthling-Mestekemper, Christoph Kuhn, Wolfgang Vorbrüggen, Martin Welcker, Stefan Kleinert
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundSafety recommendations for Janus kinase inhibitors (JAKi) issued by the European Medical Agency (EMA) in 2023 could potentially influence treatment patterns for rheumatoid arthritis (RA) drugs, but little is known about the impact of these
Externí odkaz:
https://doaj.org/article/8fdf039605db47819e20145e68fee00c